| Similar Articles |
|---|
 |
The Motley Fool
February 4, 2005
Stephen D. Simpson |
Ventana's Window to Growth Can this accelerating diagnostics company grow into its valuation?   |
BusinessWeek
October 1, 2007
Conrad Wilson |
A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution. |
The Motley Fool
July 16, 2007
Brian Orelli |
Ventana Says No, We Can't Talk In many ways, Ventana is actually a perfect match for Roche. But for now, this hostile takeover bid is stalled. Investors, take note. |
The Motley Fool
August 22, 2007
Brian Orelli |
Yes? No? Maybe So? Roche is still after Ventana. While longtime investors are happy that Roche pointed out Ventana's undervaluation to the rest of the world, current investors think Roche's offer is still too low. |
The Motley Fool
October 30, 2007
Brian Orelli |
Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note. |
The Motley Fool
August 24, 2007
Brian Orelli |
Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it. |
Chemistry World
January 27, 2012
Sarah Houlton |
Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach. |
The Motley Fool
January 6, 2012
Brian Orelli |
Don't Read Too Much Into This Partnership While the partnership is not a sign that Roche will buy Aeterna Zentaris, there's no doubt that the development of AEZS-108 makes the biotech a more attractive takeout candidate. |
The Motley Fool
June 20, 2008
Brian Orelli |
Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics. |
BusinessWeek
October 4, 2004
Gene G. Marcial |
TriPath Imaging: The Prognosis Is Good Another diagnostic outfit has caught the eye of investors. Its stock, at $10 in April, sild to $7 in August but has since crept up to $8.30. |
